WNTR is up 68%+ since October 2025, while BTC and IBIT are down over 20%, establishing WNTR as a high-beta inverse BTC ...

Small-cap stocks are leading the way in 2026 amid easing rates and earnings growth after lagging for a decade. Discover the ...

GK Quiz Today, 13 January, 2026; Latest Current Affairs Questions & Answers: A structured Current Affairs Quiz routine ...

India’s flexi-cap mutual fund category has grown into a Rs 5.5 lakh crore giant, making it the largest segment across equity, ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S ...

Struggling with blind pimples? Learn how to treat cystic acne fast with dermatologist-approved products and proven at-home ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

Many investors who go down this path do not implement well-diversified allocations Read more at The Business Times.

ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...

The First Trust Energy AlphaDEX ETF (FXN) was launched on May 8, 2007, and is a passively managed exchange traded fund designed to offer broad exposure to the Energy - Broad segment of the equity ...

Kanazawa University, have captured real-time images showing how a key brain enzyme organizes itself to help memory formation.

FDA approves Mitapivat, the first oral treatment for thalassemia anemia, helping reduce transfusion needs and raise ...